Talecris Biotherapeutics is a US-based biotherapeutic and biotechnology company that discovers, develops and produces critical care treatments for people with life-threatening disorders in a variety of therapeutic areas including immunology, pulmonology, neurology, hemostasis and critical care.

The company announced today that it had signed a definite agreement to be acquired by Grifols, a global healthcare company based in Spain which is a leading producer of plasma protein therapies. Grifols will acquire Talecris for a combination of cash and newly-issued Grifols non-voting shares valued at $3.4 billion. Talecris shareholders will receive $19 in cash and 0.641 in Grifols shares for each share of Talecris. The Grifols will be listed on the NASDAQ.

The combination of Grifols and Talecris will create a vertically integrated and diversified international plasma protein therapies company. The new company brings together complementary geographic footprints and products, as well as increased manufacturing scale. For more information on the details of the combined company, please visit either www.talecris.com or www.grifols.com.

Grifols chairman and CEO Victor Grifols commented on the deal, “The acquisition of Talecris furthers our vision to better serve patients and health care professionals with innovative products, a strong clinical research capability and new research into recombinant therapies. We look forward to combining the strengths of both companies to improve the quality of the lives of patients around the world, while positioning the enlarged group for long term profitable growth.”

Let us hear your thoughts below: